Skip to content
drillr.ai
Sign up

INDV

Indivior Pharmaceuticals Inc

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US

$34.94
+0.32%
Ask drillr

  • Aug 3, 2026, 10:30 UTC

    Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a definitive agreement to merge in an all-stock merger of equals, creating a combined CNS biopharmaceutical company named Supernus, Inc.

    Source:

  • Aug 3, 2026, 00:00 UTC

    Indivior Pharmaceuticals repurchased shares totaling $175 million in Q2 2026 at an average price of $37.52 per share, bringing year-to-date repurchases to $300 million.

  • Aug 3, 2026, 00:00 UTC

    Indivior Pharmaceuticals reported Q2 2026 total net revenue of $343 million, up 14% year-over-year, with GAAP net income of $122 million and diluted EPS of $0.98.

  • Aug 3, 2026, 00:00 UTC

    Citibank N.A. committed to provide a $650 million senior secured term loan to Indivior to fund the special dividend in connection with the merger.